Diversify Wealth Management LLC Increases Stock Position in Danaher Corporation (NYSE:DHR)

Diversify Wealth Management LLC boosted its position in shares of Danaher Corporation (NYSE:DHR - Free Report) by 25.3% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 10,254 shares of the conglomerate's stock after buying an additional 2,068 shares during the quarter. Diversify Wealth Management LLC's holdings in Danaher were worth $2,040,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the stock. Robeco Schweiz AG raised its stake in shares of Danaher by 26.0% during the 1st quarter. Robeco Schweiz AG now owns 327,058 shares of the conglomerate's stock worth $67,047,000 after purchasing an additional 67,513 shares in the last quarter. Ramsay Stattman Vela & Price Inc. increased its holdings in shares of Danaher by 1.2% during the 1st quarter. Ramsay Stattman Vela & Price Inc. now owns 68,912 shares of the conglomerate's stock valued at $14,127,000 after acquiring an additional 803 shares during the last quarter. Cerity Partners LLC increased its holdings in shares of Danaher by 11.8% during the 1st quarter. Cerity Partners LLC now owns 337,409 shares of the conglomerate's stock valued at $69,170,000 after acquiring an additional 35,712 shares during the last quarter. Vision Capital Management Inc. acquired a new position in shares of Danaher during the 1st quarter valued at about $461,000. Finally, Telos Capital Management Inc. increased its holdings in shares of Danaher by 0.6% during the 1st quarter. Telos Capital Management Inc. now owns 45,281 shares of the conglomerate's stock valued at $9,283,000 after acquiring an additional 250 shares during the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

DHR has been the topic of a number of research analyst reports. The Goldman Sachs Group lowered their target price on Danaher from $260.00 to $240.00 and set a "neutral" rating on the stock in a report on Wednesday, April 23rd. Argus lowered their target price on Danaher from $260.00 to $240.00 in a report on Wednesday, April 23rd. TD Cowen raised their target price on Danaher from $240.00 to $248.00 and gave the company a "buy" rating in a report on Wednesday, April 23rd. HSBC decreased their price objective on Danaher from $270.00 to $240.00 in a report on Friday, April 25th. Finally, Wolfe Research decreased their price objective on Danaher from $275.00 to $220.00 and set an "outperform" rating on the stock in a report on Monday, April 7th. Three analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $248.43.

Danaher Stock Down 2.5%

NYSE DHR traded down $5.01 during trading hours on Tuesday, reaching $192.74. 4,521,829 shares of the company's stock were exchanged, compared to its average volume of 3,517,815. The company has a market capitalization of $137.94 billion, a price-to-earnings ratio of 37.43, a price-to-earnings-growth ratio of 2.88 and a beta of 0.77. Danaher Corporation has a one year low of $171.00 and a one year high of $281.70. The company's 50-day moving average is $196.06 and its two-hundred day moving average is $205.89. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.43.

Danaher (NYSE:DHR - Get Free Report) last released its earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.26. Danaher had a net margin of 15.81% and a return on equity of 10.80%. The business had revenue of $5.74 billion during the quarter, compared to analysts' expectations of $5.58 billion. On average, analysts forecast that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 0.66%. Danaher's dividend payout ratio (DPR) is 24.85%.

Insiders Place Their Bets

In other Danaher news, EVP Christopher Paul Riley sold 15,805 shares of the business's stock in a transaction that occurred on Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the sale, the executive vice president directly owned 15,179 shares of the company's stock, valued at $3,005,442. The trade was a 51.01% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Chairman Steven M. Rales sold 1,250,000 shares of the business's stock in a transaction that occurred on Monday, May 12th. The stock was sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the completion of the transaction, the chairman owned 3,105,808 shares in the company, valued at $611,036,665.92. This trade represents a 28.70% decrease in their position. The disclosure for this sale can be found here. 11.20% of the stock is currently owned by company insiders.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.